| Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025 |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data from a matching-adjusted indirect comparison study evaluating taletrectinib versus entrectinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be presented in a poster session at ISPOR 2025, the Professional Society for Health Economics and Outcomes Research's annual conference, taking place M. |
businesswire.com |
2025-05-13 20:05:00 |
Czytaj oryginał (ang.) |
| Nuvation Bio Inc. (NUVB) Q1 2025 Earnings Call Transcript |
Nuvation Bio Inc. (NYSE:NUVB ) Q1 2025 Earnings Call May 7, 2025 4:30 PM ET Company Participants J.R. DeVita - Investor Relations David Hung - Founder, President and Chief Executive Officer Colleen Sjogren - Chief Commercial Officer Philippe Sauvage - Chief Financial Officer Conference Call Participants Gregory Renza - RBC Capital Markets Kaveri Pohlman - Clear Street Soumit Roy - Jones Research Michael Yee - Jefferies Yaron Werber - TD Cowen Operator Good afternoon and welcome to the Nuvation Bio First Quarter 2025 Financial Results and Business Update Conference Call. |
seekingalpha.com |
2025-05-12 02:05:36 |
Czytaj oryginał (ang.) |
| Nuvation Bio Inc. (NUVB) Reports Q1 Loss, Tops Revenue Estimates |
Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.16 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago. |
zacks.com |
2025-05-07 23:40:37 |
Czytaj oryginał (ang.) |
| Nuvation Bio: A Real Shot To Move The Needle In Lung Cancer Subtypes |
Nuvation Bio's taletrectinib shows strong efficacy in ROS1-positive NSCLC, with a 90.1% response rate, and FDA approval is likely by June 2025. Financially robust, Nuvation Bio has over three years of cash runway and additional liquidity options to support taletrectinib's launch and ongoing research. Despite strong data, competition from Bristol Myers Squibb's repotrectinib and other ROS1 players, and market hesitancy pose challenges for taletrectinib's market penetration. |
seekingalpha.com |
2025-05-07 13:07:27 |
Czytaj oryginał (ang.) |
| Nuvation Bio to Present at The Citizens Life Sciences Conference |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today announced that Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in a fireside chat at The Citizens Life Sciences Conference on Thursday, May 8, 2025, at 10:00 a.m. ET in New York, NY. A live webcast of the presentation will be available on the Nuvation Bio website at https://investors.nuvationbio.com/investors/. An ar. |
businesswire.com |
2025-05-01 20:05:00 |
Czytaj oryginał (ang.) |
| Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025 |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on solving some of the toughest challenges in cancer treatment, will announce results for the first quarter of 2025 on Wednesday, May 7, 2025. Company executives will provide an overview of its programs, summarize its commercial strategy for taletrectinib, and review financial results beginning at 4:30 p.m. ET. The U.S. Food and Drug Administration assigned taletrectinib's New Drug Application with a Pr. |
businesswire.com |
2025-04-22 20:05:00 |
Czytaj oryginał (ang.) |
| Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025, at 10:00 a.m. PT/1:00 p.m. ET in Las Vegas, NV. An audio. |
businesswire.com |
2025-04-02 12:00:00 |
Czytaj oryginał (ang.) |
| Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025 |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new nonclinical data for taletrectinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25–30, 2025 in Chicago, Illinois. Presentation Overview: Title: Taletrectinib, a next generation selective ROS1 inhibitor,. |
businesswire.com |
2025-03-25 18:45:00 |
Czytaj oryginał (ang.) |
| Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025 |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new data from a matching-adjusted indirect comparison study evaluating taletrectinib versus crizotinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be reported in a mini oral presentation at the European Lung Cancer Congress taking place March 26–29, 2025 in Paris, France. Mini Oral Presentation Overview: Ti. |
businesswire.com |
2025-03-25 10:00:00 |
Czytaj oryginał (ang.) |
| Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. “Nuvation Bio had a transformative year in 2024, marked by significant milestones. We acquired AnHeart Therapeutics, reported positive pivotal data for taletrectinib, and submitted the NDA for taletrectinib, which was accep. |
businesswire.com |
2025-03-06 18:30:00 |
Czytaj oryginał (ang.) |
| Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced non-dilutive financings of up to $250 million with Sagard Healthcare Partners (Sagard). The transaction comprises a royalty interest financing of $150 million and a senior term loan of up to $100 million. These financings strengthen Nuvation Bio's balance sheet to fully fund commercialization of taletrectinib in the U.S., if approve. |
businesswire.com |
2025-03-03 10:35:00 |
Czytaj oryginał (ang.) |
| Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, MA. A live webcast of the presentation will be available on the Nuvation Bio website at https://investors.nuvationbio.com/investo. |
businesswire.com |
2025-02-24 10:00:00 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm |
NEW YORK , Feb. 18, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nuvation Bio Inc. (NYSE: NUVB) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. |
prnewswire.com |
2025-02-18 15:49:00 |
Czytaj oryginał (ang.) |
| Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst |
Nuvation Bio, listed via SPAC in 2021, and acquired AnHeart Therapeutics last year, gaining taletrectinib, a promising ROS1 inhibitor indicated for NSCLC. The FDA has accepted Nuvation's New Drug Application for the drug, assigning it priority review and a PDUFA date of June 23, 2025. Taletrectinib shows clearly superior clinical data compared to rivals, with a potential market opportunity of ~$3.8bn by its fourth year, despite current market skepticism. |
seekingalpha.com |
2025-02-13 19:09:38 |
Czytaj oryginał (ang.) |
| Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced it has initiated an Expanded Access Program (EAP) for taletrectinib in the U.S. for the treatment of patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) when no comparable or satisfactory alternative therapy options are available. “This EAP reflects our unwavering dedication to patie. |
businesswire.com |
2025-02-03 10:00:00 |
Czytaj oryginał (ang.) |
| Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 9:00 a.m. PT in San Francisco, California. A live webcast of the presentation will be available on the Nuvation Bio website at https://investors.nuv. |
businesswire.com |
2025-01-06 18:05:00 |
Czytaj oryginał (ang.) |
| Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration |
SAN FRANCISCO and SUZHOU, China , Jan. 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announced that China's National Medical Products Administration (NMPA) has approved the second New Drug Application (NDA) of DOVBLERON® (taletrectinib adipate capsule), a next-generation ROS1 tyrosine kinase inhibitor (TKI), for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC. The approval is based on positive results from the pivotal Phase 2 TRUST-I trial (NCT04395677), a multicenter, open-label, single-arm trial that evaluated the safety, tolerability and efficiency of taletrectinib in Chinese patients with advanced ROS1-positive NSCLC. |
prnewswire.com |
2025-01-02 21:00:00 |
Czytaj oryginał (ang.) |
| U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio's New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that the U.S. FDA has accepted the company's NDA for taletrectinib, an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI), for the treatment of advanced ROS1+ NSCLC (line agnostic). The U.S. FDA has granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2. |
businesswire.com |
2024-12-23 10:00:00 |
Czytaj oryginał (ang.) |
| Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration |
SAN FRANCISCO and SUZHOU, China , Dec. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announced that China's National Medical Products Administration (NMPA) has approved a New Drug Application (NDA) of DOVBLERON ® (taletrectinib adipate capsule), a next-generation ROS1 tyrosine kinase inhibitor (TKI), for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have been previously treated with ROS1 TKIs. DOVBLERON® marks the 13th addition to Innovent's commercial portfolio, representing an innovative precision therapy expected to benefit more lung cancer patients alongside our strong TKI franchise. |
prnewswire.com |
2024-12-20 09:10:00 |
Czytaj oryginał (ang.) |
| Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference in Coral Gables, Florida, on Wednesday, December 4, 2024, at 9:10 a.m. ET. A live webcast of the fireside chat will be available on the. |
businesswire.com |
2024-11-26 10:00:00 |
Czytaj oryginał (ang.) |
| Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced the appointment of Philippe Sauvage as Chief Financial Officer (CFO). Mr. Sauvage brings over 20 years of global leadership experience in finance, operations, and commercialization within healthcare and biopharmaceutical organizations. Most recently, as Global Head of Operations and Access at Sanofi, he oversaw. |
businesswire.com |
2024-10-07 20:05:00 |
Czytaj oryginał (ang.) |
| Positive Pooled Data from Nuvation Bio's TRUST-I and TRUST-II Studies Highlight Taletrectinib's Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced positive pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies evaluating taletrectinib, an investigational next-generation ROS1 TKI. The findings will be highlighted in a poster presentation on September 14, 2024, at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain. |
businesswire.com |
2024-09-14 07:05:00 |
Czytaj oryginał (ang.) |
| Nuvation Bio to Present at the Cantor Global Healthcare Conference |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the Cantor Global Healthcare Conference in New York, NY on Thursday, September 19, 2024, at 9:45 a.m. E.T. A live webcast of the presentation will be available on the Nuvation Bio website at https://investors. |
businesswire.com |
2024-09-09 12:00:00 |
Czytaj oryginał (ang.) |
| Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced multiple updates for its taletrectinib program. Data from the global, pivotal Phase 2 TRUST-II study has been accepted for an oral presentation at WCLC 2024 taking place September 7-10 in San Diego, California. Pooled data from both pivotal Phase 2 studies, TRUST-I and TRUST-II, has been accepted for a poster pr. |
businesswire.com |
2024-07-23 20:05:00 |
Czytaj oryginał (ang.) |
| Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting |
SAN FRANCISCO and SUZHOU, China , June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, next-generation ROS1 tyrosine kinase inhibitor (TKI), were published today in the Journal of Clinical Oncology (JCO) and will be highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Data were reported from 173 patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) who were treated with taletrectinib. |
prnewswire.com |
2024-06-02 05:13:00 |
Czytaj oryginał (ang.) |
| Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting |
SAN FRANCISCO, U.S. and SUZHOU, China , June 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, next-generation ROS1 tyrosine kinase inhibitor (TKI), were published today in the Journal of Clinical Oncology (JCO) and will be highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Data were reported from 173 patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) who were treated with taletrectinib. |
prnewswire.com |
2024-06-02 00:00:00 |
Czytaj oryginał (ang.) |
| Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, its investigational next-generation ROS1 tyrosine kinase inhibitor (TKI), were published today in the Journal of Clinical Oncology (JCO) and will be highlighted in an oral presentation at the 2024 American Society of Clini. |
businesswire.com |
2024-06-01 12:10:00 |
Czytaj oryginał (ang.) |
| Nuvation Bio to Present at the Jefferies Global Healthcare Conference |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced today that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will participate in a hybrid presentation at the Jefferies Global Healthcare Conference in New York, NY on Wednesday, June 5, 2024, at 1:30 p.m. ET. A live webcast. |
businesswire.com |
2024-05-29 20:05:00 |
Czytaj oryginał (ang.) |
| Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the first quarter ended March 31, 2024, and provided a business update. “The first quarter of 2024 included multiple significant events for Nuvation Bio. We announced and subsequently completed the acquisition of AnHeart Therapeutics, whic. |
businesswire.com |
2024-05-14 20:05:00 |
Czytaj oryginał (ang.) |
| Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that updated data from the Phase 2 TRUST-I clinical study (NCT04395677) evaluating taletrectinib in patients in China with ROS1-positive non-small cell lung cancer (NSCLC) will be reported in an oral presentation at the 2024 American Society of Clinical Oncolo. |
businesswire.com |
2024-04-24 14:01:00 |
Czytaj oryginał (ang.) |
| Nuvation Bio Completes Acquisition of AnHeart Therapeutics |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the completion of the acquisition of AnHeart Therapeutics Ltd. (AnHeart), a late-stage, global biopharmaceutical company developing novel precision therapies for people with cancer. With the acquisition's completion, AnHeart is now a wholly-owned subsidiary of. |
businesswire.com |
2024-04-10 20:01:00 |
Czytaj oryginał (ang.) |
| Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate |
Nuvation Bio has acquired an advanced pipeline candidate, taletrectinib, leading to a surge in market cap approaching $1 billion. Taletrectinib has shown promising clinical activity in treating ROS1-positive non-small cell lung cancer and has Breakthrough Therapy Designation. Nuvation Bio also now has other pipeline candidates, including safusidenib and NUV-868, and has sufficient liquid assets to fund operations for years without help. |
seekingalpha.com |
2024-03-31 14:00:00 |
Czytaj oryginał (ang.) |
| Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms. Sjogren will lead the Company's commercial strategy and operations, including marketing, sales, and market access. “We are thrilled to welcome Colleen as Nuvation Bio's first Chief Commercial Officer. She is an. |
businesswire.com |
2024-03-28 10:00:00 |
Czytaj oryginał (ang.) |
| Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, and AnHeart Therapeutics Ltd. (AnHeart), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced that the companies have entered into a definitive agreement for Nuvation Bio to acquire AnHeart in an all-stock transaction (th. |
businesswire.com |
2024-03-25 09:00:00 |
Czytaj oryginał (ang.) |
| Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors |
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that the first patient has been dosed in a Phase 1/2 study of NUV-1511, the Company's first DDC to enter the clinic. “Dosing the first patient with NUV-1511 marks a significant milestone for our proprietary DDC platform, from which we are developing potent oncology-focused chime. |
businesswire.com |
2024-03-14 18:05:00 |
Czytaj oryginał (ang.) |
| Nuvation Bio Inc. (NUVB) Is Up 25.28% in One Week: What You Should Know |
Does Nuvation Bio Inc. (NUVB) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2024-03-08 15:01:19 |
Czytaj oryginał (ang.) |